Executive Overview

Chimeric antigen receptor T-cell (CAR T) therapy stands as one of the most remarkable breakthroughs in modern oncology. By genetically reprogramming a patient’s own immune cells to selectively target, bind to, and destroy malignant cells, this cellular immunotherapy has redefined survival expectations for individuals battling aggressive hematologic malignancies. Conditions such as relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL)—which historically offered dismal prognoses and limited palliative alternatives—are now met with durable remissions and long-term survival for a subset of patients.

However, the extraordinary clinical promise of CAR T therapy is currently met with severe geopolitical and economic bottlenecks. Within Latin America, Brazil stands alone as the sole country providing access to commercial CAR T therapies. Yet, this milestone masks profound systemic inequalities. The widespread implementation of CAR T in Brazil is hindered by complex manufacturing logistics, a rigid requirement for highly specialized medical infrastructure, and a prohibitive price tag averaging USD 500,000 per patient for commercial products.

To confront these hurdles, the Americas Health Foundation convened a multidisciplinary panel of Brazilian leaders spanning oncology, regulatory science, public health policy, patient rights, and healthcare technology in July 2025. Their findings, published in Frontiers in Hematology (Vol. 5, 2026), expose a fractured healthcare landscape divided between the public Unified Health System (Sistema Único de Saúde, SUS) and the private insurance market. With treatment timelines stretching to 150 days and many patients forced into legal litigation to secure coverage, the report outlines a comprehensive roadmap for domestic manufacturing, regulatory modernization, and value-based reimbursement models designed to secure equitable access.

Detailed Chronology & Regulatory Evolution

The integration of CAR T-cell therapy into Brazil’s medical matrix has been marked by a rapid yet turbulent regulatory evolution. The journey began in earnest following the landmark U.S. Food and Drug Administration (FDA) approvals of anti-CD19 cellular products in 2017. As global clinical trials demonstrated unprecedented complete remission rates—such as the 81% complete remission rate observed within three months in pediatric and young adult B-ALL patients in the pivotal ELIANA study—Brazilian health authorities faced mounting pressure to establish pathways for domestic patient access.

By the early 2020s, Brazil’s National Health Surveillance Agency (ANVISA) began granting commercial marketing authorizations. In 2022, ANVISA approved tisagenlecleucel (Kymriah®) for R/R B-ALL and axicabtagene ciloleucel (Yescarta®) for large B-cell lymphoma following two or more lines of systemic therapy. This was followed in 2023 by approvals for brexucabtagene autoleucel (Tecartus®) targeting mantle cell lymphoma and precursor B-ALL, and ciltacabtagene autoleucel (Carvykti®) for multiple myeloma.

Despite these regulatory clearances, the operational reality for patients remained grim. Between 2020 and 2024, only 104 patients successfully received CAR T-cell therapy nationwide—a fraction of the estimated 23,000 annual diagnoses of non-Hodgkin lymphomas and leukemias in Brazil. Administrative bottlenecks, limited certified treatment centers, and a lack of clear reimbursement mandates from the National Regulatory Agency for Private Health Insurance and Plans (ANS) created an impasse.

To bridge this gap, patients and civil society organizations increasingly turned to the courts. Leveraging Brazil’s constitutional guarantee of health as a fundamental right, litigants achieved a 96% success rate when private insurers denied coverage on the grounds that CAR T was absent from mandatory lists. Legislative updates, including Law 14.454/2022, further reinforced patient rights by allowing coverage for non-listed technologies under specific evidentiary criteria. Simultaneously, the launch of national clinical trials in 2024 for homegrown CAR T constructs signaled a decisive shift toward domestic self-reliance.

Supporting Context & Metrics: Clinical Efficacy, Economics, and Disparities

Clinical Landscapes and Toxicities

The clinical efficacy of CAR T-cell therapies is undeniable, yet it demands careful risk-benefit navigation due to acute toxicities. Anti-CD19 constructs operate independently of human leukocyte antigen (HLA) restriction, utilizing extracellular antibody-derived recognition domains fused with intracellular costimulatory signaling domains (such as CD28 or 4-1BB) to drive T-cell persistence.

Pivotal trials illustrate their potency:

• ZUMA-1 (Axicabtagene ciloleucel / DLBCL): Demonstrated an overall response rate (ORR) of 82% and a complete response (CR) rate of 58%, with a 5-year overall survival (OS) rate of 42.6%.
• JULIET (Tisagenlecleucel / DLBCL): Reported an ORR of 52% and a CR rate of 40%, with a 5-year OS of 43%.
• ELIANA (Tisagenlecleucel / Pediatric B-ALL): Achieved an 81% complete remission rate at 3 months, with a 12-month event-free survival rate of 59%.

Real-world registries, such as France’s DESCAR-T registry, confirm these outcomes while highlighting that agents like axi-cel often yield higher response rates at the cost of increased acute toxicities—primarily cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Managing these complications requires specialized multidisciplinary training and intensive care infrastructure, which remains scarce outside major metropolitan centers in Brazil.

Public Versus Private Disparities

Brazil’s healthcare ecosystem is split sharply into two domains:

1. The Unified Health System (SUS): Serves roughly 75% of the population. While legally committed to universal access, it faces severe infrastructural deficits, resulting in average treatment delays of 100 to 150 days. Many patients experience disease progression or death while awaiting approval, mirroring global data showing that over 20% of referred patients never reach infusion.
2. The Private Insurance Market: Governed by the ANS "Rol de Procedimentos," private insurers have historically resisted covering high-cost cellular therapies. This friction drives rampant judicialization, with patients forced to secure emergency injunctions to access life-saving infusions.

Domestic Biomanufacturing Initiatives

Recognizing that imported commercial products priced at USD 500,000 are unsustainable, Brazil is pioneering local production models to slash costs:

• Fiocruz and Caring Cross Collaboration: A strategic partnership aimed at establishing national manufacturing capacity for lentiviral vectors and CAR T cells, targeting a public health delivery cost of approximately USD 35,000 per dose.
• INCA and Children’s Hospital of Philadelphia (CHOP): An alliance focused on building an automated CAR T manufacturing facility tailored for pediatric oncology.
• Academic Trials: Institutions such as the University of São Paulo’s Center for Cell-Based Therapy (CTC) in Ribeirão Preto and the Butantan Institute have launched phase 1/2 clinical trials for domestically engineered CAR T constructs, aiming to democratize access across the public care continuum.

Official Statements and Expert Perspectives

The convening of the Americas Health Foundation expert panel brought together prominent voices in Brazilian hematology, public health, and regulatory science.

"The commercial cost of imported CAR T therapy represents an insurmountable wall for our public healthcare infrastructure," noted lead investigator Dr. Renato Luiz Guerino-Cunha. "By relying solely on international pharmaceutical supply chains, we condemn thousands of patients with rapidly progressive hematologic malignancies to palliative care while they await administrative approvals or judicial resolutions."

Public health advocates underscored that the ethical implications of current delays extend far beyond financial balance sheets. When patients succumb to disease progression during protracted waiting periods, the failure is structural and systemic.

Regulatory experts emphasized that modernizing ANVISA’s frameworks must go hand in hand with economic innovation. Implementing value-based pricing models—such as outcome-based risk-sharing agreements modeled after successful international programs in the UK, Spain, and France—is viewed as essential to aligning manufacturer pricing with real-world patient survival. Furthermore, integrating civil society organizations into governance bodies like CONITEC ensures that health technology assessments reflect the lived realities of patients and their families.

Future Outlook & Strategic Recommendations

To transform CAR T-cell therapy from an exclusive privilege into an accessible pillar of universal health coverage, the expert panel outlined a pragmatic, multi-tiered action plan for stakeholders:

By fostering domestic manufacturing independence, modernizing regulatory pathways, and embracing value-based healthcare financing, Brazil has the potential to overcome its current infrastructural barriers. Successfully executing these reforms will not only save thousands of lives domestically but also establish a replicable, high-impact framework for resource-limited healthcare systems worldwide.